4//SEC Filing
Kirchgraber Paul R 4
Accession 0001127602-23-006642
CIK 0000920148other
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 9:54 AM ET
Size
8.7 KB
Accession
0001127602-23-006642
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Sale
Common Stock
2023-02-21$250.58/sh−8,000$2,004,675→ 9,069 total - Exercise/Conversion
Non-qualified Stock Options
2023-02-21−3,000→ 4,300 totalExercise: $182.51From: 2021-02-04Exp: 2030-02-03→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2023-02-21$182.51/sh+3,000$547,530→ 17,069 total
Footnotes (3)
- [F1]The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- [F2]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- [F3]The option vested in three equal annual installments beginning on the date reflected in this column.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001791393
Filing Metadata
- Form type
- 4
- Filed
- Feb 22, 7:00 PM ET
- Accepted
- Feb 23, 9:54 AM ET
- Size
- 8.7 KB